CRBP

Corbus Pharmaceuticals Holdings, Inc.

Healthcare
Biotechnology
$150M market cap

Forecast run · Sep 14, 2026Upside rank 976 of 3,136

Model Signal

ForecastQ Daily Probabilities

45.4%

36.6%

41.1%

Analyst Consensus

Recommendation2.13/5 Buy

Last price$8.12

Price target$33.67

Implied move+314.7%

Analysts16

ForecastQ Portfolios

CRBP is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.